Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasm Metastasis 4Leukemia, Myeloid, Acute 3Glioblastoma 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Osteosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1

Interventions

amivantamab 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Cetuximab 1(225)Ac-DOTA-c(RGDyK) 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × NIH × Locally Recurrent Skin Squamous Cell Carcinoma × Clear all
NCT07042295 2026-06-03

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

National Cancer Institute (NCI)

Phase 2 Suspended
86 enrolled

Locally Recurrent Skin Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡